Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

With China’s population undergoing demographic aging and growing public awareness of cancer screening, the clinical need for the management of urologic malignancies is steadily increasing. Radiotherapy, a mainstay of oncologic treatment, has evolved rapidly—progressing from old techniques to intensity‑modulated radiotherapy (IMRT), and from conventional fractionation regimens to stereotactic body radiation therapy (SBRT). Precision radiotherapy is now emerging as a pivotal modality in the management of urologic cancers. Professor Ningning Lu, affiliated to the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, has dedicated years to the field of precision radiotherapy for urologic tumors, amassing substantial clinical expertise and a robust research portfolio. UroStream invited Professor Lu to deliver an in-depth review of the clinical applications of precision radiotherapy in urologic malignancies, thereby providing evidence-based insights and practical guidance for clinicians.
Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma 

Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma 

With the rapid progress of clinical research, immunotherapy has demonstrated substantial value across multiple treatment settings in renal cell carcinoma (RCC). In particular, immune-based combination regimens have reshaped the treatment landscape of advanced RCC. At the 9th West China Uro-Oncology Tianfu Academic Conference & the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee, Professor Pei Dong from Sun Yat-sen University Cancer Center delivered a keynote lecture titled “Rational Reflections Amid the Surge of Immunotherapy in RCC.” After the session, Oncology Frontier – Urology Frontier invited Prof. Dong for an in-depth discussion on the evolving role of neoadjuvant therapy, adjuvant immunotherapy, and precision strategies for FH-deficient RCC. 
Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?

Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?

In recent years, the incidence of urological malignancies in China has risen steadily. Prostate, bladder, and kidney cancers now rank among the most common malignancies in the country, posing a serious threat to public health. The Department of Urology at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS), has long been dedicated to the diagnosis and treatment of urological tumors. With extensive experience in laparoscopic and minimally invasive surgery as well as multidisciplinary cancer management, it stands as a leading force in China’s field of urologic oncology.
Precision Targeted Therapy for Bladder Cancer Reaches a New Milestone: Professor Xu Tao’s Team from Peking University People’s Hospital Demonstrates Potent Synergistic Effects Through Combination Treatment 

Precision Targeted Therapy for Bladder Cancer Reaches a New Milestone: Professor Xu Tao’s Team from Peking University People’s Hospital Demonstrates Potent Synergistic Effects Through Combination Treatment 

Bladder cancer is one of the most common malignant tumors of the genitourinary system. In recent years, the emergence of antibody-drug conjugates (ADCs) has brought new hope for patients with advanced bladder cancer. Among them, Enfortumab Vedotin (EV) — an ADC targeting the tumor antigen Nectin-4 — has been hailed as a “precision-guided missile.” However, the molecular mechanisms underlying the variability in EV’s therapeutic response have not been fully elucidated.